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Abstract 
Chronic heart failure is an epidemic of the XXI century that is confirmed by its prevalence, progressive course and place in 
the structure of morbidity causes and mortality from CVD. In recent decades, significant progress has been made in the 
development of therapeutic algorithms of treatment of CHF using the different groups of the drugs and their combinations, but 
the specifics of the treatment of elderly patients remains poorly understood. The steady aging of the population of developed 
countries increases the share of cardiovascular diseases in the overall structure of morbidity that leads to an increase of the 
number of elderly patients in the practice of doctors of many specialties. It should be noted that elderly patients are more 
frequently suffered from CVD such as IHD, CHF, arrhythmias, diabetic cardiomyopathy and hypertension. Myocardial 
dyssynchrony is one of the main causes of chronic heart failure (CHF) in the elderly. At the same time, normal aging is 
associated with deterioration of global left ventricular dyssynchrony. This publication covers the mechanisms of fibrous 
remodeling of the aging heart, formation of the fibrosis and dyssynchrony. There are presented the information about the 
details of the types of dyssynchrony, diagnosis, course and influence on the progression of CHF. The publication also presents 
the changes of myocardial synchrony after the improvement of myocardial blood supply as a result of revascularization. Most 
likely this is due to decrease of the mass of the hibernated myocardium and improving of its energy supply and conductivity, 
because the other positive changes caused by revascularization are usually developed later. 
 
 
Introduction 
 
The steady aging of the population of developed 
countries increases the share of cardiovascular diseases 
(CVD) in the overall structure of morbidity that leads 
to an increase of the number of elderly patients in the 
practice of doctors of many specialties. As a result, the 
understanding of geriatric aspects of cardiology is an 
important element of knowledge not only for the 
modern cardiologist, but also for geriatrician, family 
doctor and general practitioner [1]. 
Until recently, it was believed that only 
symptomatic treatment of CVD in elderly patients was 
necessary and that the drug intervention had weak 
effect on the prognosis for the life at this age. 
However, recent large clinical studies strongly suggest 
that the patient's age is not a contraindication for the 
active medical and surgical treatment of many CVD – 
coronary heart disease (CHD), stenotic atherosclerosis 
of the main arteries, arrhythmias and impaired cardiac 
conduction. In addition, the absolute risk of 
cardiovascular complications in elderly patients is high 
and CVD treatment of this category of the patients is 
considered as more effective than in young and 
middle–aged patients. 
Chronic heart failure is an epidemic of the XXI 
century that is confirmed by its prevalence, progressive 
course and place in the structure of morbidity causes 
and mortality from CVD [2]. The steady increase in the 
number of patients with CHF in economically 
developed countries is primarily associated with the 
whole aging of the population, an expansion of cardiac 
risk factors and improvement of the survival of patients 
with cardiovascular disease [3]. According to experts, 
the prevalence of CHF in the European population 
ranges from 0.4% to 2%. Annually CHF develops in 
1% of persons older than 60 years and in 10% of those 
that is older than 75 years. As a result, the elderly 
population (with age that is greater than or equal to 65 
years) will double from 2010 to 2040 and the number 
of the elderly persons will increase from 40 million in 
2010 to 81 million in 2040 [4]. Since there is a 
worldwide intensive growth of the elderly population 
and progression of the clinical manifestations of CVD 
according to the ageing, it is supposed that the 
prolongation of the life expectancy will significantly 
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increase the expenses on the health care. It should be 
noted that ageing nowadays has been identified as the 
dominant risk factor for CVD. At the same time, in the 
elderly, the aging heart is characterized by both 
structural and functional changes [5]. Among 
asymptomatic individuals without clinical symptoms of 
CVD, there are with aging significantly more often 
diagnosed increase of the left ventricular (LV) mass, 
decrease of myocardial perfusion, lag of regional 
myocardial contraction and systolic myocardial 
dysfunction [6]. 
 
Material and Methods 
 
In recent decades, significant progress has been 
made in the development of therapeutic algorithms of 
treatment of CHF using the different groups of the 
drugs and their combinations, but the specifics of the 
treatment of elderly patients remains poorly 
understood. The main reason for this was the 
purposeful exclusion of the persons who are over 75 
years old from the most part of prospective clinical 
trials (CT) of treatment CHF – primarily women who 
are more than a half of the all elderly persons with 
CHF and persons with concomitant diseases who are 
also elderly ones, as a rule. Therefore, before obtaining 
of CT data that is specially designed for the elderly 
with CHF, it should be guided by the proven principles 
of treatment of CHF for middle-aged people, taking 
into account the age characteristics of the elderly and 
their individual contraindications. The prognosis for 
elderly and senile patients remains serious regardless of 
the stage of the disease. In this regards, it is natural to 
continue the searching of mechanisms of CHF 
development and progression with using of 
personalized approaches for different age groups. All 
possible measures aimed at the struggle against the 
aging of the heart, improve the health of the elderly, 
their quality of life, reduce morbidity and mortality 
from CVD. 
It should be noted that elderly patients are more 
frequently suffered from CVD such as IHD, CHF, 
arrhythmias, diabetic cardiomyopathy and hypertension 
[7]. Risk factors and main diseases lead to a gradual 
decrease of the heart function, and development of 
fibrosis is a key component of this impairment.  
The mechanisms of fibrous remodeling of the aging 
heart are well studied in both clinical and experimental 
studies. Fibrous remodeling of the heart is promoted by 
the predominance of synthesis of I-III collagen types 
over their degradation that leads to the accumulation of 
excess fibers. Age induced collagen restructuring is 
characterized by interstitial and perivascular 
accumulation of type I collagen and defective 
activation of reparative fibroblasts in response to action 
of growth factors that leads to scarring and unfavorable 
relaxation remodeling [8]. Fibrous remodeling of the 
aging heart is characterized by structural and functional 
alterations, including left ventricular (LV) hypertrophy, 
diastolic and systolic dysfunction of the heart. It is 
shown that normal aging is associated with the 
deterioration of global LV dyssynchrony due to the 
elongation of isovolumic timings and the Tei index that 
leads to a reduction of the time of filling and ejection. 
In this case, the systolic and electrical function of LV 
does not depend on age, but diastolic and synchronous 
functions are significantly age related [9]. The collagen 
accumulation in the aging heart leads to a progressive 
increase in the stiffness of the ventricles and 
impairment of diastolic function. Aging also interferes 
into the balance of matrix metalloproteinases and tissue 
inhibitors of matrix metalloproteinases [10] that 
increases the residual myocyte size and myocardial 
thickness [11] followed by reactive fibrosis and 
increased cardiac stiffness. Diastolic dysfunction plays 
a dominant role in the pathogenesis of heart failure and 
impairment of exercise tolerance in the elderly [12]. 
Framingham study of structural and functional 
alterations of the heart depending on the patients age 
[13] and Baltimore Longitudinal Study of Aging [14] 
demonstrated that according to the aging of the healthy 
population it is increased the prevalence of LV 
hypertrophy accompanied by impairment of diastolic 
heart function. Respectively subsequent fibrotic 
remodeling and pathological activation of matrix-
degrading pathways promote the heart inotropic 
dysfunction, progressive dilatation of heart ventricles, 
impairment of the cardiac systolic function and 
conduction disturbance [15]. 
Intraventricular dyssynchrony (DS) is one of the 
important prognostic factors in patients with heart 
diseases. In the modern understanding, DS is the 
dissociation of the contractions of the heart chambers 
and myocardial segments that is happened due to 
impairment of the impulse conduction that in turn leads 
to lowering of the cardiac pumping function and 
increasing of energy consumption by the myocardium. 
Kinetic impairment and formation of the asynergic 
zones in LV myocardium provoke the pathological 
remodeling with progressive LV dilatation that in turn 
leads to increased tension of the ventricular walls and 
worsening of cardiac contractile function.  
 
Results and Discussion 
 
Desynchronization is the result of myocardial 
fibrosis, especially in patients with ischemic heart 
disease, regardless of the degree of clinical 
manifestations. It was found that the impairment of the 
mechanical synchronicity of the left ventricle (LV) 
during the aging can be explained by fibrosis and 
increased lipid containing in elderly hearts [16]. 
Regional interstitial fibrosis is certainly associated with 
LV dysfunction regardless of global LV function. It is 
shown that interstitial myocardial fibrosis and ID 
coexist at an early stage of many CVD [17]. It is 
founded that aging alters the LV diastolic function due 
to increase of regional diastolic asynchrony. Indicators 
of diastolic asynchrony increase with aging, while 
indexes of systolic synchrony do not depend on the age 
[18]. Angiography with radionuclides demonstrated 
that aging is associated with a lag and decrease of early 
diastolic filling that is associated with regional LV 
dyssynchrony. Fonseca et al. also showed that there is 
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increase of regional asynchrony in elderly [19] and 
aging is associated with a progression of dyssynchrony 
degree. 
It is important because the elderly population is 
increased and we need to identify new methods of 
management of aging induced cardiac dysfunction. 
LV synchronicity has an important impact on the 
efficiency of LV functioning. Delayed electrical 
activation and a weakened coordination between 
excitation and contraction lead to a dispersion of 
regional mechanical activation known as 
intraventricular dyssynchrony that has a negative effect 
on cardiac performance [20]. LV mechanical 
discoordination leads to impairment of its contractility, 
abnormal relaxation, stretching of the contractile 
segments and positive left ventricular remodeling with 
progressive LV dilatation that causes increase of 
ventricle wall tension and worsening of LV contractile 
function. Incomplete systole, caused by mechanical 
dyssynchrony, can lead to increase of the LV filling 
pressure and, ultimately, to alteration of the LV 
diastolic function [21]. Progressive dilatation and 
reduced contractility of the left ventricle via increasing 
degree of tension of chordal apparatus and reducing of 
closing speed of the mitral valve, promote the 
development or increase of mitral regurgitation (MR). 
Uncoordinated activation of papillary muscles can 
further weaken the overall LV contractility by 
increasing of the MR severity. Uncoordinated 
contraction of the LV basal segments during the systole 
leads to enlargement of the annulus of the mitral valve 
and changing of the mitral valve leaflets orientation 
that promote increase of the mitral regurgitation [22]. 
Cardiac DS is divided into electrical and mechanical 
ones. Electric DC is associated with retardation of the 
ventricle conductivity that leads to extended duration 
of QRS [23]. Mechanical DS is a mechanical 
discoordination that is most often associated with 
simultaneous contraction and stretching of different 
segments of the LV, as well as time delays of peak 
contraction from one segment to another [24]. 
Disorders of intraventricular conduction are recorded in 
15-47% of patients with CHF, it is manifested by the 
extension of the QRS complex of the ECG, that is more 
often due to left bundle branch block (LBBB) (25-36% 
of the cases) and less frequent due to the right bundle 
branch block (RBBB) (in 46% of the cases). Severity 
of the electrical dyssynchrony in CHF cases closely 
correlated with lowering of the LV ejection fraction 
and the level of mitral regurgitation. In addition, the 
width of the ventricular complex of the ECG is an 
important prognostic criterion; its increasing is 
accompanied by the growth of the mortality rate and 
incidence of sudden cardiac death in CHF cases. 
Systolic asynchrony is often revealed in patients with 
CHF, the share of the patients with extension of QRS 
complexes reaches to 50%. The length of QRS 
complexes is used as a marker of mechanical DS in 
patients with severe systolic dysfunction [25], and it is 
a criterion for resynchronizing heart therapy in cases of 
CHF with systolic dysfunction. It is proved that QRS 
extension is associated with growth of mortality rate 
[26]. At the same time, several studies have 
demonstrated a poor correlation between the duration 
of the QRS complex and the indices of mechanical 
asynchrony. Recent studies have shown that DS is 
revealed in 30-40% of patients with normal length of 
QRS complex and it poor correlates with 
electromechanical DS that is detected on the basis of 
tissue Doppler data. It was found that mechanical DS is 
a predictor of deterioration of CHF, regardless of the 
duration of QRS and LV ejection fraction (EF) [27]. 
Yu CM et al. shown that about 30% of patients with 
CHF and length of QRS more then 120 ms did not 
demonstrate significant reverse of LV remodeling in 
response to resynchronization therapy (RST), while 
patients with narrow QRS with proven mechanical DS 
had a positive response to RST [28]. Thus, mechanical 
DS is more important than electrical DS, because it is 
associated with a higher risk of unfavorable outcomes 
and can be a predictor of serious cardiac events in 
patients with CHF [29]. Regardless of the QRS length, 
the patients with CHF could form systolic and diastolic 
LV asynchrony that causes to ineffective contraction 
and relaxation. It was shown that dilation and decrease 
of LV systolic function are predictors of systolic 
asynchrony, while diastolic dysfunction and QRS 
extension are predictors of diastolic heart asynchrony 
[30]. Both systolic and diastolic dissynchrony was 
observed in 40% of patients with narrow QRS 
complexes and about 70% of patients with wide QRS 
complexes [31]. 
Echocardiography (EchoCG) has been several years 
applied in basic and translational researches for 
studying of the heart disease models, including age-
related cardiac dysfunction. Echocardiographic 
evaluation of DS is widely applied because it is non-
invasive, widely available and has no risks or side 
effects. The technique ranges from conventional 
Doppler EchoCG to more advanced Doppler tissue 
imaging (DTI), three-dimensional echocardiography, 
and two-dimensional speckle tracking imaging (STI), 
and more recently for 3D Speckle Tracking 
Echocardiography (3D-STE) [32]. New EchoCG 
methods, such as tissue synchronization imaging (TSI) 
and 2D speckle tracking, allow to analyze the peak 
systolic velocity and deformational delays of various 
LV walls and, therefore, to evaluate mechanical DS 
[33]. Evaluation of deformation parameters (the 
magnitude and speed of deformation) allows to 
differentiate passive (movement of cicatricial tissue) 
and active movements (contraction) of LV walls that 
make this type of the study more reliable. However, the 
real potential for evaluating of myocardial 
dyssynchrony in the context of aging and cardiac 
dysfunction requires further study. 
There are 3 types of mechanical DS: 
atrioventricular DS (in which the time of atrial 
contraction does not immediately precede to the 
contraction of the ventricles); interventricular DS (in 
which the contractions of the right and left ventricles 
are not simultaneous); intraventricular DS (in which 
different walls of the LV are not contracted 
simultaneously). 
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EchoCG criterion for interventricular DS is 
interventricular mechanical delay (IVMD) more than 
40 ms (it is time between the onset of systolic flows in 
the aorta (APEI) and pulmonary trunk (PPEI)). The 
sensitivity of the method is 66%, its specificity is 55%. 
The criteria of interventricular DS is the maximum 
inter-segment delay (Ts) more than 100 ms [34] and 
the index of mechanical dissynchrony (Ts-SD) more or 
equal than 31 ms. Ts-SD is the best predictor of reverse 
remodeling. In patients with QRS length more than 150 
ms, this indicator has 96% sensitivity of and 78% 
specificity, for the patients with a borderline QRS 
duration (120-150 ms), the sensitivity is 83% and 
specificity is 86% [35]. 
De Sutter et al. founded that cases of symptomatic 
CHF have 18% patients with systolic intraventricular 
dyssynchrony for the cases with preserved EF and 36% 
of dyssynchrony for the cases with low (<40%) EF. 
However, if QRS extension is more or equal to 120 ms, 
the prevalence of systolic intraventricular 
dyssynchrony in cases of CHF with preserved EF 
increases nearly to 50% that is comparable with the 
appropriate indexes of the patients with low EF and a 
QRS length more or equal to 120 ms [36, 37]. 
LV myocardial ischemia is one of the main causes 
of DS. CHF that is caused by ischemia has prevalence 
of DS from 20.8% to 79.6% [38] and this DS is 
associated with a significantly increased risk of cardiac 
events in patients that is treated. Intraventricular 
asynchronous has a prognostic value in patients before 
and after coronary artery bypass grafting (CABG). 
Gibson et al. reported about resolving of LV 
dyssynchrony after CABG in 12 (86%) from 14 
patients with preserved EF. The presence of severe 
myocardial DS before and after revascularization is 
associated with high hospital and long-term mortality 
in patients with ischemic CHF. In cases without DS, 
survival is associated with a greater improvement of 
CHF symptoms and LV EF, compared to patients with 
DS [38]. DS of the heart is an essential pathogenetic 
factor of development and progression of CHF with 
reduced EF on the background of IHD in elderly. 
Coronary revascularization, in particular CABG, is one 
of the most adequate methods of restoring the 
synchronicity of contractility and functional 
capabilities of the myocardium. Indications for 
revascularization in patients with ischemic CHF are 
unstable angina and severe coronary artery stenosis 
according to coronary angiography. The risk of death 
in this group of patients is increased and ranges from 5 
to 30%. Treatment of ischemic CHF that is not 
accompanied by high functional class of angina 
pectoris is a problem, because the randomized 
controlled trials of such category of the patients have 
not been performed. It is established that plan of 
examination of patients with CHF and confirmed CHD 
have to include the assessment of myocardium 
viability. Some prospective and retrospective studies, 
meta-analyses revealed improvement in LV function 
and survival after revascularization of cases of 
ischemized but still viable myocardium. If the viable 
myocardium is absent, revascularization is ineffective 
and surgical treatment should be avoided because of its 
risks. Patients with severe LV dilation have low 
probability to improve the EF in spite of presence of 
the viable myocardium [39]. After myocardial 
revascularization, there was a decrease in the some 
parameters that are the criteria of DS, in particular, the 
frequency expansion of QRS more or equal 120 ms by 
31%, interventricular mechanical delay by 14.5%, 
intraventricular delay by 20.1% and presystolic mitral 
regurgitation by 16.5%. These changes suggest the 
improvement of myocardial synchrony after the 
improvement of myocardial blood supply as a result of 
revascularization. Most likely this is due to decrease of 
the mass of the hibernated myocardium and improving 
of its energy supply and conductivity, because the other 
positive changes caused by revascularization are 
usually developed later. This suggests that the aging of 
the heart is characterized by structural and functional 
changes of the myocardium, including firstly diastolic 
and later systolic dysfunction, concentric LV 
hypertrophy, fibrous remodeling with myocardial 
dissynchronization and subsequent formation of 
eccentric myocardial hypertrophy, diminishing of 
inotropic reserve and decrease of tolerance to physical 
activity [40]. 
 
Conclusions 
 
Despite the significant progress achieved in the 
treatment of CHF in recent years, the problem of 
manifestation, progression and prognosis of this 
category of patients remains relevant. Recently, DS is 
considered as one of the possible pathogenetic aspects 
of the CHF progression. In our opinion, this 
mechanism underlies the deterioration of patients' 
condition and the progression of CHF with chronic 
coronary artery disease in elderly. Further study of the 
role of DS in the pathogenesis of CHF that is induced 
by IHD will allow to obtain deeper understanding of 
this problem which, in turn, create conditions for the 
finding of the new drugs with the necessary pleiotropic 
pharmacological effects. 
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